Breast Cancer

Researchers tested whether certain patients with HER2-positive breast cancer may eventually be eligible for non-surgical management.

The results of a new study add to the list of benefits seen with exercise among breast cancer survivors: reducing the risk of cardiovascular disease.

Researchers evaluated whether breast cancer patients with hypothyroidism at diagnosis or who develop it later have an increased risk of recurrence or death.

The long-term results of the phase III HannaH trial confirmed the similarity between the subcutaneous and intravenous formulation of trastuzumab in patients with HER2+ breast cancer.

Researchers tested omitting chemotherapy from a treatment regimen involving dual blockade with pertuzumab and trastuzumab in patients with metastatic HER2+ breast cancer.

Researchers will discuss new findings on continuous vs intermittent chemotherapy schedules in advanced breast cancer at the ESMO Breast Cancer Congress.

Researchers tested whether TP53 mutation status can determine the function of estrogen receptor-beta (ESR2) in patients with triple-negative breast cancer.

A study of genetic testing in ovarian and breast cancer patients found substantial disparities in testing rates for ovarian cancer patients.

In this slideshow, various clinical guidelines on breast cancer screening are summarized, including the ACP's recent recommendations that have come under some scrutiny.

Dr. McArthur discusses the latest results of immunotherapy trials in the treatment of triple-negative breast cancer.

Cancer Network spoke with Hank Schmidt, MD, about the 10-year follow-up results of the EORTC AMAROS trial of radiotherapy vs surgery of the axilla in breast cancer patients with a positive sentinel node.

The combination of trastuzumab and paclitaxel 'represents an important step forward in de-escalating therapy' for HER2+ breast cancer.

A genomic and proteomic analysis of HER2+ breast cancer cell lines that are resistant to trastuzumab found a deregulation of the cell death pathway known as TRAIL.

Researchers tested whether the use of alternative control probes to classify HER2 status in breast cancer could lead to substantial false positives.

A small early-phase trial tested the addition of the oncolytic virus T-VEC to neoadjuvant chemotherapy in patients with triple-negative breast cancer.

Researchers looked at the role of biomarkers associated with systemic inflammation among patients with triple-negative breast cancer.

The updated version incorporates biologic factors to refine and improve the prognostic stratification of patients with breast cancer.

Among the updates are expanded treatment options, including a recently approved immunotherapy regimen for locally advanced or metastatic disease.

The US Food and Drug Administration has approved the subcutaneous administration of trastuzumab for patients with HER2-overexpressing breast cancer.

An early-phase trial tested the combination of pembrolizumab with trastuzumab in patients with PD-L1–positive, trastuzumab-resistant, advanced HER2+ breast cancer.

Researchers conducted a validation study of four breast cancer risk models currently in use.

The addition of denosumab to adjuvant aromatase inhibitor therapy offered improved outcomes in women with postmenopausal HR+ early breast cancer.

The researchers looked at cardiac outcomes among a group of HER2+ breast cancer patients treated with trastuzumab who had an asymptomatic LVEF decline of < 50%.

The study findings suggest that disease-free survival can continue to be used as a surrogate endpoint in the setting of early HER2+ breast cancer.

Researchers compared hypofractionated radiotherapy vs a conventional regimen to study outcomes and toxicity in breast cancer patients.

Researchers conducted a study to evaluate the short-term clinical outcomes of varying approaches to immediate implant-based breast reconstruction in the UK.

Cancer Network spoke with Dr. Michael Holick about the role of and effectiveness of vitamin D in cancer prevention.

A large study looked at previously confirmed and newly discovered associations between several genes and breast cancer and ovarian cancer risk.

In this review, we focus primarily on describing locoregional and systemic management strategies for isolated locoregional recurrences manifesting as isolated first-failure events following mastectomy or breast-conserving therapy.

An oncology pharmacist discusses how to manage neutropenic toxicity from treatment with CDK4/6 inhibitors for HR-positive breast cancer.